MindArk PE: Mindark: Rapportkommentar Q2’24 - Kalqyl (Kalqyl)

Ependion: Ependion: Attractive end market exposure (Carnegie)

Gapwaves: Gapwaves: Sensrad announces first commercial contract (Carnegie)

Guard Therapeutics: Guard Therapeutics: Intervju - Meddelar studiestart (Penser Access)

Absolicon Solar Collector: Absolicon: Rapportkommentar Q2’24 - Kalqyl (Kalqyl)

Cereno Scientific: Cereno Scientific: CS1 granted OMPD, complementing FDA ODD - Edison (Edison Investment Research)

Ascelia Pharma: Ascelia Pharma: Secures full support from the completed Rights Issue (Redeye)

SKAKO: SKAKO (One-pager): FY'24 revenue guidance lowered but with record order received in Q3 (HC Andersen Capital via Inderes)

Maximum Entertainment: Maximum Entertainment: Here is what the investors are asking (Redeye)

Cheffelo: Cheffelo: Here is what the investors are asking (Redeye)

Circio Holding: Circio ASA: Here is what the investors are asking (Redeye)

Fiskars: Fiskars: Risk of profit warning in the air (Inderes)

Vaisala: Hexagon and Vaisala: Quality companies are the ones to buy, especially in difficult times (Inderes)

Refine Group: Aktieanalys och intervju med Refine Group (Analyst Group)

Carlsquare/Vontobel weekly trading note: Micron stock due for a rebound? (Carlsquare)

Elon: ANALYS Elon: Andra kvartalet banar väg för ett starkt 2024 (Analysguiden)

Carlsquare weekly letter: Time for a new bump in the road? (Carlsquare)

Verve: Verve Q2´24: Vinner marknadsandelar (Inderes)

Herantis Pharma: Herantis receives approval for Phase Ib clinical trial (Inderes)

Qlosr Group: Qlosr - To close the subscription model chapter (ABG Sundal Collier)

Systemair: Systemair: Highlights from Carnegie’s Small & Mid Cap Seminar 2024 (Carnegie)

Vibrosense Dynamics: Vibrosense Dynamics: Rapportkommentar Q4’23/24 - Kalqyl (Kalqyl)

MapsPeople: MapsPeople: Ready to invest in growth activities after fully subscribed rights issue (HC Andersen Capital via Inderes)

Maximum Entertainment: Maximum Entertainment: New board proposal (Redeye)

Ogunsen: Ogunsen - Tough Q2, but it's not getting worse (ABG Sundal Collier)

Enrad: Research update Enrad, Q2 2024: Enrad should invest in growing markets (Carlsquare)

Enrad: Analysuppdatering Enrad, kv2 2024: Enrad behöver satsa på växande marknader (Carlsquare)

Xintela: Xintela: Activities below the surface (Västra Hamnen)

North Media: North Media (One-pager): Revenue guidance raised, but synergy-related investments lower EBIT forecast (HC Andersen Capital via Inderes)

H&M: H&M: We believe Q3 has been tough (Inderes)

Kempower: Kempower: News flow does not support expectations for stronger sales (Inderes)

LifeClean International: LifeClean International: Here is what the investors are asking (Redeye)

Stockpicker: Yubico – substantiell omvärdering (Stockpicker)

Th1ng: TH1NG: Ask questions to Redeye's analyst (Redeye)

VEF: ANALYS VEF: Kraftigt förbättrat resultat för Creditas i kvartalet (Analysguiden)

Lipigon Pharmaceuticals: ANALYS Lipigon Pharmaceuticals: Långsam start för ny studie (Analysguiden)

Kentima Holding: INITIERINGSANALYS Kentima: Europamarknad hägrar (Analysguiden)

SyntheticMR: ANALYS SyntheticMR: Organisationsproblem i USA orsakar prognosmiss (Analysguiden)

Gullberg & Jansson: Gullberg & Jansson: Rapportkommentar Q2’24 - Kalqyl (Kalqyl)

Th1ng: TH1NG: Intervju med vd Klas Westholm (Redeye)